Multidrug resistance in cancer: role of ATP–dependent transporters
The DOI matches its Crossref record; 167 of the 168 references it cites were found in a registry or an index.
Abstract
Chemotherapeutics are the most effective treatment for metastatic tumours. However, the ability of cancer cells to become simultaneously resistant to different drugs--a trait known as multidrug resistance--remains a significant impediment to successful chemotherapy. Three decades of multidrug-resistance research have identified a myriad of ways in which cancer cells can elude chemotherapy, and it has become apparent that resistance exists against every effective drug, even our newest agents. Therefore, the ability to predict and circumvent drug resistance is likely to improve chemotherapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A common mechanism of multidrug resistance consists in the overexpression of cancer drug–extruding ABC transporters in malignant cells (58).”
From SRC kinase drives multidrug resistance induced by KRAS-G12C inhibition (2024) · cites this paper as [58]
In the citing paper
“Prior exposure to taxanes during treatment of mCRPC can induce resistance mechanisms, including upregulation of efflux pumps or mutations in tubulin, that may compromise the efficacy of microtubule inhibitor-based ADCs246,247.”
From The evolving landscape of antibody-drug conjugates (ADCs) for treatment of prostate cancer (2025) · cites this paper as [247]
Citations
Cites
A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants
Juliano, R. L., & Ling, V. (1976) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(76)90160-7 · Cited by 3,296
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104 · cited 1×
“But why can some patients be cured by these approaches and others respond transiently or incompletely? Host and tumour genetic alterations, epigenetic changes and tumour environment all seem to contribute to the complex story of cancer drug resistanc”
BackgroundOverexpression of a Transporter Gene in a Multidrug-Resistant Human Lung Cancer Cell Line
Cole, S. P. C., Bhardwaj, G., Gerlach, J. H., Mackie, J. E., Grant, C. E., Almquist, K. C., Stewart, A. J., Kurz, E. U., Duncan, A. M. V., & Deeley, R. G. (1992) · Science · doi:10.1126/science.1360704 · Cited by 3,037
p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
Lowe, S. W., Ruley, H. E., Jacks, T., & Housman, D. E. (1993) · Cell · doi:10.1016/0092-8674(93)90719-7 · Cited by 2,925
A multidrug resistance transporter from human MCF-7 breast cancer cells
Doyle, L. A., Yang, W., Abruzzo, L. V., Krogmann, T., Gao, Y., Rishi, A. K., & Ross, D. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15665 · Cited by 2,322 · cited 1×
“cgi?l=9429">ABCG2 — also known as MXR (mitoxantrone-resistance gene), BCRP (breast cancer resistance protein) or ABC-P (ABC transporter in placenta”
BackgroundNormalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
Jain, R. K. (2001) · Nature Medicine · doi:10.1038/nm0901-987 · Cited by 2,184 · cited 1×
“Recent studies have emphasized the importance of the tumour vasculature and an appropriate pressure gradient for adequate drug delivery to the tumou”
BackgroundBIOCHEMICAL, CELLULAR, AND PHARMACOLOGICAL ASPECTS OF THE MULTIDRUG TRANSPORTER
Ambudkar, S. V., Dey, S., Hrycyna, C. A., Ramachandra, M., Pastan, I., & Gottesman, M. M. (1999) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.39.1.361 · Cited by 2,059 · cited 1×
“asp?DrugCode=A%2D10166&DrugName=PACLITAXEL%2CSEMI%2DSYNTHETIC+INTRAVEN%2E&DrugType=1">paclitaxel”
Self-citationChen, C.-J., Chin, J. E., Ueda, K., Clark, D. P., Pastan, I., Gottesman, M. M., & Roninson, I. B. (1986) · Cell · doi:10.1016/0092-8674(86)90595-7 · Cited by 1,898
Self-citationA family of drug transporters: the multidrug resistance-associated proteins
Borst, P., Evers, R., Kool, M., & Wijnholds, J. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.16.1295 · Cited by 1,751 · cited 1×
“The discovery of MRP1 stimulated a genomic search for homologues, leading to the discovery of eight additional members of the ABCC subfamily of transporters, of which six have been studied in some detai”
BackgroundThe Human ATP-Binding Cassette (ABC) Transporter Superfamily
Dean, M., Rzhetsky, A., & Allikmets, R. (2001) · Genome Research · doi:10.1101/gr.184901 · Cited by 1,748
Research works printed but not linked: 3
- Solary, E. et al. Sufficient levels of quinine in the serum circumvent the multidrug resistance of the human leukemic cell line K562/ADM. Cancer 68, 1714–1719 (1991). · doi:10.1002/1097-0142(19911015)68:8<1714::aid-cncr2820680811>3.0.co;2-2
- Abraham, J. et al. A phase I study of the novel P-glycoprotein (PGP) antagonist, XR9576 in combination with vinorelbine. Proc. Am. Soc. Clin. Oncol. 20, 287 (2001).
- Fedeli, L. et al. Pharmacokinetics of vincristine in cancer patients treated with nifedipine. Cancer 64, 1805–1811 (1989). · doi:10.1002/1097-0142(19891101)64:9<1805::aid-cncr2820640908>3.0.co;2-d
Cited by
Items 401–500 of 1,041
Tumor‐associated macrophages (TAMs) depend on ZEB1 for their cancer‐promoting roles
Cortés, M., Sanchez‐Moral, L., de Barrios, O., Fernández‐Aceñero, M. J., Martínez‐Campanario, M., Esteve‐Codina, A., Darling, D. S., Győrffy, B., Lawrence, T., Dean, D. C., et al. (2017) · The EMBO Journal · doi:10.15252/embj.201797345 · Cited by 174
“…and other cancers (Chau et al , 2011; Silva et al , 2011); Mdr1 (Abcb1) , an efflux drug transporter associated with chemotherapy resistance (Gottesman et al , 2002); and Cd74, which is expressed by both F4/80 low macrophages and ovarian cancer cells and that activates CCL2 transcription…”
Evolution of the vertebrate ABC gene family: analysis of gene birth and death
Annilo, T., Chen, Z.-Q., Shulenin, S., Costantino, J., Thomas, L., Lou, H., Stefanov, S., & Dean, M. (2006) · Genomics · doi:10.1016/j.ygeno.2006.03.001 · Cited by 175
Kim, H. G., Hien, T. T., Han, E. H., Hwang, Y. P., Choi, J. H., Kang, K. W., Kwon, K., Kim, B., Kim, S. K., Song, G. Y., et al. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01101.x · Cited by 172
“MDR arises by several mechanisms in cancer, but is frequently associated with enhanced drug efflux via broad-specificity, ATP-dependent, ATP-binding cassette (ABC) family transporters (herein termed multidrug transporters) (Gottesman et al., 2002).”
BackgroundInfluentialPredictive Markers in Breast and Other Cancers: A Review
Duffy, M. J. (2005) · Clinical Chemistry · doi:10.1373/clinchem.2004.046227 · Cited by 174
“The prototype member, ABCB1 (also known as Pglycoprotein, P-170, PGP, or MDR1) is a broad-spectrum multidrug efflux pump that possess 12 transmembrane domains and 2 ATP-binding sites (46, 47).”
BackgroundMarine Sponge Natural Products with Anticancer Potential: An Updated Review
Calcabrini, C., Catanzaro, E., Bishayee, A., Turrini, E., & Fimognari, C. (2017) · Marine Drugs · doi:10.3390/md15100310 · Cited by 166
“Furthermore, they did not modify the cytotoxic profile of the above reported anticancer drugs when administered to cell lines knockout for Pgp or expressing other types of resistance proteins (i.e., MDR1, MDR7, or BCRP) [166,167].”
BackgroundInfluentialShen, W., Liu, W., Yang, H., Zhang, P., Xiao, C., & Chen, X. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.02.011 · Cited by 176
“Among these mechanisms, the overexpression of A TP-binding cassette (ABC) transporters that contrib u ed to increased drug efflux appears to be the major form f tumor resistance [5, 6].”
BackgroundTang, H., Chen, D., Li, C., Zheng, C., Wu, X., Zhang, Y., Song, Q., & Fei, W. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.118782 · Cited by 173
Ionizing Radiation Induces Stemness in Cancer Cells
Ghisolfi, L., Keates, A. C., Hu, X., Lee, D.-K., & Li, C. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043628 · Cited by 165
“ABC) [12,13,14], DNA repair enzymes [15,16] and anti-apoptotic proteins [17,18,19], which renders them highly resistant to conventional cancer therapies including chemotherapy and radiation.”
BackgroundDrug resistance, predictive markers and pharmacogenomics in colorectal cancer
Longley, D. B., Allen, W. L., & Johnston, P. G. (2006) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2006.08.001 · Cited by 171
Paclitaxel And Docetaxel Resistance: Molecular Mechanisms and Development of New Generation Taxanes
Galletti, E., Magnani, M., Renzulli, M. L., & Botta, M. (2007) · ChemMedChem · doi:10.1002/cmdc.200600308 · Cited by 164
Li, W.-Q., Wang, Z., Hao, S., He, H., Wan, Y., Zhu, C., Sun, L.-P., Cheng, G., & Zheng, S.-Y. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b01540 · Cited by 172
Chemotherapy and chemo-resistance in nasopharyngeal carcinoma
Guan, S., Wei, J., Huang, L., & Wu, L. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112758 · Cited by 168
Madhusudhan, A., Reddy, G., Venkatesham, M., Veerabhadram, G., Kumar, D., Natarajan, S., Yang, M.-Y., Hu, A., & Singh, S. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15058216 · Cited by 170
“Thus, this drug delivery system is excellent for use in MDR cells overexpressing p-glycoprotein, as it evades this resistance mechanism by slow nucleus targeted drug release.”
BackgroundMulti-functional nanocarriers for targeted delivery of drugs and genes
Jabr-Milane, L., van Vlerken, L., Devalapally, H., Shenoy, D., Komareddy, S., Bhavsar, M., & Amiji, M. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.04.016 · Cited by 171
Kibria, G., Hatakeyama, H., & Harashima, H. (2014) · Archives of Pharmacal Research · doi:10.1007/s12272-013-0276-2 · Cited by 171
“1), is encoded by the ABCB1/MDR1 gene (Gottesman et al. 2002).”
BackgroundDiscovering Natural Product Modulators to Overcome Multidrug Resistance in Cancer Chemotherapy
Wu, C.-P., Ohnuma, S., & V. Ambudkar, S. (2011) · Current Pharmaceutical Biotechnology · doi:10.2174/138920111795163887 · Cited by 171
“However, only three major ABC drug transporters, including P-glycoprotein (Pgp; ABCB1), multidrug resistance protein 1 (MRP1; ABCC1) and ABCG2 (BCRP; MXR), are believed to seriously affect cancer chemotherapy [2, 4].”
BackgroundMinderman, H., O’Loughlin, K. L., Pendyala, L., & Baer, M. R. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0914-3 · Cited by 170
“MDR is frequently associated with overexpression of cell membrane proteins that function as energydependent drug efflux pumps, preventing substrate drugs from reaching intracellular targets (1).”
BackgroundZeng, L., Pan, Y., Tian, Y., Wang, X., Ren, W., Wang, S., Lu, G., & Wu, A. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.04.006 · Cited by 171
“However, in MCF-7/ADR cells, DOX was hardly present due to the block of over-expressed P-glycoprotein [49], as shown in Fig.”
BackgroundImaging the Function of P-Glycoprotein With Radiotracers: Pharmacokinetics and In Vivo Applications
Kannan, P., John, C., Zoghbi, S. S., Halldin, C., Gottesman, M. M., Innis, R. B., & Hall, M. D. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.138 · Cited by 166
Self-citationBui, B. P., Nguyen, P. L., Lee, K., & Cho, J. (2022) · Cancers · doi:10.3390/cancers14246054 · Cited by 194
“The high expression of the human MDR1 gene and its encoded transporter, P-glycoprotein (P-gp), can reduce the intracellular concentrations of numerous chemotherapeutic agents, such as vinca alkaloids, anthracyclines, paclitaxel, and doxorubicin, by acting as a drug efflux pump [100,101].”
BackgroundClinical Relevance of P-Glycoprotein in Drug Therapy
Lin, J. H., & Yamazaki, M. (2003) · Drug Metabolism Reviews · doi:10.1081/dmr-120026871 · Cited by 167
“These include disruption of apoptotic signaling pathways, gene amplification, activation of DNA repair, and overexpression of efflux transporters (Gottesman et al., 2002).”
BackgroundTang, S. C., Lagas, J. S., Lankheet, N. A. G., Poller, B., Hillebrand, M. J., Rosing, H., Beijnen, J. H., & Schinkel, A. H. (2012) · International Journal of Cancer · doi:10.1002/ijc.26000 · Cited by 165
miR-200c Inhibits Melanoma Progression and Drug Resistance through Down-Regulation of Bmi-1
Liu, S., Tetzlaff, M. T., Cui, R., & Xu, X. (2012) · The American Journal of Pathology · doi:10.1016/j.ajpath.2012.07.009 · Cited by 165
Hall, M. D., Salam, N. K., Hellawell, J. L., Fales, H. M., Kensler, C. B., Ludwig, J. A., Szakács, G., Hibbs, D. E., & Gottesman, M. M. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm800861c · Cited by 167
Self-citationYan, Y., Cao, S., Liu, X., Harrington, S. M., Bindeman, W. E., Adjei, A. A., Jang, J. S., Jen, J., Li, Y., Chanana, P., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.97828 · Cited by 169
“CX3CR1 + CD8 + T cells express ABCB1 (Figure 3), a member of the ABC superfamily of drug transporters (30).”
BackgroundOvercoming multidrug resistance in cancer: Recent progress in nanotechnology and new horizons
Majidinia, M., Mirza‐Aghazadeh‐Attari, M., Rahimi, M., Mihanfar, A., Karimian, A., Safa, A., & Yousefi, B. (2020) · IUBMB Life · doi:10.1002/iub.2215 · Cited by 167
“Members of the second class are not transported into cells but affect transporter function.(8) However, studies showed that the ABC transporter inhibitors had generally negative or only modestly positive effectiveness in reversing MDR, such that preclinical trials of first and second generation ABC transport inhibitor…”
BackgroundMethod(2019) · Profiles of Drug Substances, Excipients and Related Methodology · doi:10.1016/bs.podrm.2018.11.001 · Cited by 159
Bosch, T. M., Meijerman, I., Beijnen, J. H., & Schellens, J. H. M. (2006) · Clinical Pharmacokinetics · doi:10.2165/00003088-200645030-00003 · Cited by 167
Marcus, A. I., Peters, U., Thomas, S. L., Garrett, S., Zelnak, A., Kapoor, T. M., & Giannakakou, P. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413471200 · Cited by 170
Marquez, B., & Van Bambeke, F. (2011) · Current Drug Targets · doi:10.2174/138945011795378504 · Cited by 165
“The role of these MDR transporters, and of P-gp in particular, is well described in the context of resistance to anticancer drugs [9, 10].”
BackgroundATP-binding cassette efflux transporters and MDR in cancer
Pote, M. S., & Gacche, R. N. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103537 · Cited by 161
Kuo, M. D., Gollub, J., Sirlin, C. B., Ooi, C., & Chen, X. (2007) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2007.04.031 · Cited by 168
“Tumors have the ability to acquire resistance to drugs that share different chemical structures and mechanisms of action, more broadly known as multidrug resistance, through the activation or repression of certain genes or pathways (30).”
BackgroundResistance to Chemotherapy in Cancer: A Complex and Integrated Cellular Response
Mellor, H. R., & Callaghan, R. (2008) · Pharmacology · doi:10.1159/000115967 · Cited by 168
“The protein was named the permeability or P-gp and is now known to be a member of the ATP binding cassette (ABC) superfamily of transporters. The presence of P-gp was rapidly observed as a negative prognostic factor in cancer and impacted on the efficacy of a multitude of chemotherapeutic agents. The ability of P-gp t…”
BackgroundGene expression alterations in doxorubicin resistant MCF7 breast cancer cell line
AbuHammad, S., & Zihlif, M. (2013) · Genomics · doi:10.1016/j.ygeno.2012.11.009 · Cited by 164
“One of the most common changes in doxorubicin resistance is the up-regulation of many transporters genes [12].”
BackgroundStructural Basis of Energy Transduction in the Transport Cycle of MsbA
Dong, J., Yang, G., & Mchaourab, H. S. (2005) · Science · doi:10.1126/science.1106592 · Cited by 168
Zhao, X., Chen, Q., Li, Y., Tang, H., Liu, W., & Yang, X. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.03.003 · Cited by 166
Chen, K. G., Valencia, J. C., Gillet, J., Hearing, V. J., & Gottesman, M. M. (2009) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2009.00630.x · Cited by 162
“The substrates of the transporters range from small ions, sugars, and peptides to more complex organic molecules (Dean and Annilo, 2005; Deeley et al., 2006; Doyle and Ross, 2003; Gottesman and Ling, 2006; Gottesman et al., 2002; Robey et al., 2007; Szakacs et al., 2006).”
BackgroundSelf-citationDunne, L. W., Huang, Z., Meng, W., Fan, X., Zhang, N., Zhang, Q., & An, Z. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2014.03.003 · Cited by 164
“The reduced sensitivity to chemotherapy agents in 3D cultures has been attributed to increased cellematrix interactions and the elevated expression of transporters [20,31,51,52].”
BackgroundJuang, V., Chang, C., Wang, C., Wang, H., & Lo, Y. (2019) · Small · doi:10.1002/smll.201903296 · Cited by 164
Biomaterials and 3D Bioprinting Strategies to Model Glioblastoma and the Blood–Brain Barrier
Tang, M., Rich, J. N., & Chen, S. (2021) · Advanced Materials · doi:10.1002/adma.202004776 · Cited by 160
Mirrahimi, M., Abed, Z., Beik, J., Shiri, I., Shiralizadeh Dezfuli, A., Mahabadi, V. P., Kamran Kamrava, S., Ghaznavi, H., & Shakeri-Zadeh, A. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.01.005 · Cited by 168
Milane, L., Duan, Z., & Amiji, M. (2011) · Molecular Pharmaceutics · doi:10.1021/mp1002653 · Cited by 161
Stadler, P. F., Chen, J. J.-L., Hackermuller, J., Hoffmann, S., Horn, F., Khaitovich, P., Kretzschmar, A. K., Mosig, A., Prohaska, S. J., Qi, X., et al. (2009) · Molecular Biology and Evolution · doi:10.1093/molbev/msp112 · Cited by 163
Mechanisms of antiepileptic drug resistance
Sisodiya, S. M. (2003) · Current Opinion in Neurology · doi:10.1097/00019052-200304000-00013 · Cited by 164
Decreasing GSH and increasing ROS in chemosensitivity gliomas with IDH1 mutation
Shi, J., Sun, B., Shi, W., Zuo, H., Cui, D., Ni, L., & Chen, J. (2014) · Tumor Biology · doi:10.1007/s13277-014-2644-z · Cited by 163
Cheng, Y., Muroski, M. E., Petit, D. C. M. C., Mansell, R., Vemulkar, T., Morshed, R. A., Han, Y., Balyasnikova, I. V., Horbinski, C. M., Huang, X., et al. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.12.028 · Cited by 158
Yu, G., Zhou, J., Shen, J., Tang, G., & Huang, F. (2016) · Chemical Science · doi:10.1039/c6sc00531d · Cited by 163
Combating subclonal evolution of resistant cancer phenotypes
Brady, S. W., McQuerry, J. A., Qiao, Y., Piccolo, S. R., Shrestha, G., Jenkins, D. F., Layer, R. M., Pedersen, B. S., Miller, R. H., Esch, A., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01174-3 · Cited by 163
Sang, M., Luo, R., Bai, Y., Dou, J., Zhang, Z., Liu, F., Feng, F., Xu, J., & Liu, W. (2019) · Theranostics · doi:10.7150/thno.36283 · Cited by 163
“Moreover, current chemotherapeutic drugs loose efficacy due to the rat sarcoma virus (RAS) mutation [6-8] and multi-drug resistance (MDR) [9, 10] occurs in malignant cells to combat apoptosis.”
BackgroundLu, C., & Shervington, A. (2008) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-008-9722-8 · Cited by 159
“Several studies suggested that ABCG2 may be used as a prognostic marker in acute myeloid leukaemia in combination with MRP1, LRP and P-gp [9, 33–35].”
BackgroundAryal, M., Fischer, K., Gentile, C., Gitto, S., Zhang, Y.-Z., & McDannold, N. (2017) · PLOS ONE · doi:10.1371/journal.pone.0166061 · Cited by 158
“Moreover, the presence of this protein in tumors contributes to cancer cells becoming resistant to chemotherapeutics and decreased treatment efficacy [10].”
Exploring silver nanoparticles for cancer therapy and diagnosis
Miranda, R. R., Sampaio, I., & Zucolotto, V. (2021) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2021.112254 · Cited by 171
Cancer stem cells and cancer therapy
Soltanian, S., & Matin, M. M. (2011) · Tumor Biology · doi:10.1007/s13277-011-0155-8 · Cited by 159
“Some properties of CSCs make them difficult cells to kill: CSCs maintain the property of selfprotection through the activity of multiple drug resistance transporters such as ABCB1 (P-glycoprotein) and/or ABCG2 (breast cancer resistance protein-1) [48, 116, 117].”
BackgroundSingh, R. R., Kunkalla, K., Qu, C., Schlette, E., Neelapu, S. S., Samaniego, F., & Vega, F. (2011) · Oncogene · doi:10.1038/onc.2011.195 · Cited by 155
“One mechanism of MDR is the increased expression of adenosine triphosphate binding cassette (ABC) drug transporters that mediate energy-dependent transport of drugs out of the cells against a concentration gradient, resulting in low intracellular drug concentrations (Gottesman et al., 2002).”
BackgroundOvercoming drug-resistant lung cancer by paclitaxel loaded tetrahedral DNA nanostructures
Xie, X., Shao, X., Ma, W., Zhao, D., Shi, S., Li, Q., & Lin, Y. (2018) · Nanoscale · doi:10.1039/c7nr09692e · Cited by 161
Verdon, G., Albers, S. V., Dijkstra, B. W., Driessen, A. J. M., & Thunnissen, A.-M. W. H. (2003) · Journal of Molecular Biology · doi:10.1016/s0022-2836(03)00575-8 · Cited by 160
Multidrug Resistance/P-Glycoprotein and Breast Cancer: Review and Meta-Analysis
Clarke, R., Leonessa, F., & Trock, B. (2005) · Seminars in Oncology · doi:10.1053/j.seminoncol.2005.09.009 · Cited by 159
Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate
Jordanides, N. E., Jorgensen, H. G., Holyoake, T. L., & Mountford, J. C. (2006) · Blood · doi:10.1182/blood-2006-02-003145 · Cited by 158
Yang, X., lyer, A. K., Singh, A., Choy, E., Hornicek, F. J., Amiji, M. M., & Duan, Z. (2015) · Scientific Reports · doi:10.1038/srep08509 · Cited by 158
“Paclitaxel is one of the most effective chemotherapeutic agents for ovarian cancer and is a first line drug used in the treatment of this disease; however, the eventual development of resistance to paclitaxel therapy occurs almost in all patients 8,9,12 .”
Long non-coding RNA mediated drug resistance in breast cancer
Singh, D., Assaraf, Y. G., & Gacche, R. N. (2022) · Drug Resistance Updates · doi:10.1016/j.drup.2022.100851 · Cited by 177
Wu, C., Calcagno, A. M., Hladky, S. B., Ambudkar, S. V., & Barrand, M. A. (2005) · The FEBS Journal · doi:10.1111/j.1742-4658.2005.04888.x · Cited by 159
Gouazé, V., Liu, Y.-Y., Prickett, C. S., Yu, J. Y., Giuliano, A. E., & Cabot, M. C. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2329 · Cited by 158
“Studies have shown that the MDR1 promoter can be activated directly by anticancer agents such as vincristine, daunorubicin, doxorubicin, and colchicine ( 45 );”
BackgroundBurroughs, A. K., Hochhauser, D., & Meyer, T. (2004) · The Lancet Oncology · doi:10.1016/s1470-2045(04)01508-6 · Cited by 159
Cathepsin B-cleavable doxorubicin prodrugs for targeted cancer therapy
Zhong, Y.-J., Shao, L., & Li, Y. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1754 · Cited by 173
“leading to reduced toxicity, improved specificity and the avoidance of multidrug resistance (14,15).”
BackgroundBao, L., Haque, A., Jackson, K., Hazari, S., Moroz, K., Jetly, R., & Dash, S. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2010.10.029 · Cited by 159
Mechanisms of platinum drug resistance
Ohmichi, M., Hayakawa, J., Tasaka, K., Kurachi, H., & Murata, Y. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.01.002 · Cited by 159
p53 and metabolism: from mechanism to therapeutics
Simabuco, F. M., Morale, M. G., Pavan, I. C. B., Morelli, A. P., Silva, F. R., & Tamura, R. E. (2018) · Oncotarget · doi:10.18632/oncotarget.25267 · Cited by 171
“In fact, multi-drug resistant cells have high expression of P-gp (P-glycoprotein 1), which requires ATP for its activity and therefore are more sensitive to ATP depletion [251, 252].”
ERK is a Pivotal Player of Chemo-Immune-Resistance in Cancer
Salaroglio, I. C., Mungo, E., Gazzano, E., Kopecka, J., & Riganti, C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102505 · Cited by 170
“The main transporters expressed in cancer cells include P-glycoprotein (Pgp/ABCB1), multidrug resistance related proteins (MRPs/ABCCs), and breast cancer resistance proteins (BCRP/ABCG2) [117].”
BackgroundBatrakova, E. V., Li, S., Brynskikh, A. M., Sharma, A. K., Li, Y., Boska, M., Gong, N., Mosley, R. L., Alakhov, V. Y., & Gendelman, H. E. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.01.004 · Cited by 157
Peng, X., Gong, F., Chen, Y., Jiang, Y., Liu, J., Yu, M., Zhang, S., Wang, M., Xiao, G., & Liao, H. (2014) · Cell Death & Disease · doi:10.1038/cddis.2014.297 · Cited by 154
Importance of P‐glycoprotein for drug disposition in humans
Fromm, M. F. (2003) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.33.s2.4.x · Cited by 158
Robey, R. W., Shukla, S., Finley, E. M., Oldham, R. K., Barnett, D., Ambudkar, S. V., Fojo, T., & Bates, S. E. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.12.001 · Cited by 158
“001 are known to induce resistance due to their ability to lower intracellular drug concentrations in an energy-dependent manner [1].”
BackgroundSelf-citationProfiling SLCO and SLC22 genes in the NCI-60 cancer cell lines to identify drug uptake transporters
Okabe, M., Szakács, G., Reimers, M. A., Suzuki, T., Hall, M. D., Abe, T., Weinstein, J. N., & Gottesman, M. M. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0539 · Cited by 173
“Although the levels of increased sensitivity were relatively low, ample evidence indicates that even small (2- to 4-fold) changes in drug sensitivity can have a significant effect on the clinical efficacy of anticancer treatment (2).”
BackgroundSelf-citationLi, J., Liu, F., Shao, Q., Min, Y., Costa, M., Yeow, E. K. L., & Xing, B. (2014) · Advanced Healthcare Materials · doi:10.1002/adhm.201300613 · Cited by 164
Multimodal transfer of MDR by exosomes in human osteosarcoma
TORREGGIANI, E., RONCUZZI, L., PERUT, F., ZINI, N., & BALDINI, N. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3509 · Cited by 153
Eckford, P. D. W., & Sharom, F. J. (2005) · Biochemical Journal · doi:10.1042/bj20050047 · Cited by 156
Genovese, I., Ilari, A., Assaraf, Y. G., Fazi, F., & Colotti, G. (2017) · Drug Resistance Updates · doi:10.1016/j.drup.2017.10.003 · Cited by 156
“ABCB4 is well expressed in the liver; its substrates are PC and some hydrophobic drugs, while in MDR cells ABCB4 is particularly selective for paclitaxel and vinblastine (Gottesman et al., 2002; Thomas and Coley, 2003).”
BackgroundCurrent advances on ABC drug transporters in fish
Luckenbach, T., Fischer, S., & Sturm, A. (2014) · Comparative Biochemistry and Physiology Part C Toxicology & Pharmacology · doi:10.1016/j.cbpc.2014.05.002 · Cited by 168
Conformational Motion of the ABC Transporter MsbA Induced by ATP Hydrolysis
Borbat, P. P., Surendhran, K., Bortolus, M., Zou, P., Freed, J. H., & Mchaourab, H. S. (2007) · PLoS Biology · doi:10.1371/journal.pbio.0050271 · Cited by 154
“MsbA has sequence similarity to a subclass of ABC transporters that is linked to the development of multidrug resistance in microorganisms and cancer through the extrusion of structurally dissimilar molecules [11,12].”
BackgroundChitosan- g -TPGS Nanoparticles for Anticancer Drug Delivery and Overcoming Multidrug Resistance
Guo, Y., Chu, M., Tan, S., Zhao, S., Liu, H., Otieno, B. O., Yang, X., Xu, C., & Zhang, Z. (2013) · Molecular Pharmaceutics · doi:10.1021/mp400514t · Cited by 156
Győrffy, B., Surowiak, P., Kiesslich, O., Denkert, C., Schäfer, R., Dietel, M., & Lage, H. (2005) · International Journal of Cancer · doi:10.1002/ijc.21570 · Cited by 174
“MDR1/P-glycoprotein (P-gp), modulations of apoptotic pathways, alterations in cell cycle checkpoints, repair of damaged cellular targets, and various more or less well-characterized mechanisms.(1) In particular cancers, these mechanisms may act simultaneously and may influence each other, so that clinical MDR is a com…”
BackgroundBoumendjel, A., Baubichon-Cortay, H., Trompier, D., Perrotton, T., & Pietro, A. D. (2005) · Medicinal Research Reviews · doi:10.1002/med.20032 · Cited by 175
Hari, M., Loganzo, F., Annable, T., Tan, X., Musto, S., Morilla, D. B., Nettles, J. H., Snyder, J. P., & Greenberger, L. M. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0190 · Cited by 175
“Paclitaxel resistance in KB-15-PTX/099 cells is not likely due to any ABC transporters (7, 8, 10) because no reduced accumulation of paclitaxel was observed in these cells.”
BackgroundWang, L., Lin, X., Wang, J., Hu, Z., Ji, Y., Hou, S., Zhao, Y., Wu, X., & Chen, C. (2014) · Advanced Functional Materials · doi:10.1002/adfm.201400015 · Cited by 159
NADPH Oxidases: Insights into Selected Functions and Mechanisms of Action in Cancer and Stem Cells
Skonieczna, M., Hejmo, T., Poterała-Hejmo, A., Cieślar‐Pobuda, A., & Bułdak, R. J. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/9420539 · Cited by 167
“The presence of CSCs might also explain why cancer may reoccur after treatment; most chemotherapeutic drugs act only on mature cancer cells, and CSCs have elevated levels of an ATP-binding cassette which promotes drug resistance [134].”
BackgroundFeng, H., Li, Y., Duan, X., Wang, X., Qi, C., Lam, J. W. Y., Ding, D., & Tang, B. Z. (2020) · Journal of the American Chemical Society · doi:10.1021/jacs.0c06872 · Cited by 157
Shen, J., Rees, T. W., Ji, L., & Chao, H. (2021) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2021.214016 · Cited by 159
Inorganic Nanocarriers Overcoming Multidrug Resistance for Cancer Theranostics
Lin, G., Mi, P., Chu, C., Zhang, J., & Liu, G. (2016) · Advanced Science · doi:10.1002/advs.201600134 · Cited by 149
Characterization of the organic cation transporter SLC22A16: A doxorubicin importer
Okabe, M., Unno, M., Harigae, H., Kaku, M., Okitsu, Y., Sasaki, T., Mizoi, T., Shiiba, K., Takanaga, H., Terasaki, T., et al. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.05.174 · Cited by 154
Gottesman, M. M., & Pastan, I. H. (2015) · Journal of the National Cancer Institute · doi:10.1093/jnci/djv222 · Cited by 148
Self-citationLiu, J.-N., Bu, W., Pan, L.-M., Zhang, S., Chen, F., Zhou, L., Zhao, K., Peng, W., & Shi, J. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.06.035 · Cited by 153
Yang, H., Chen, Y., Chen, Z., Geng, Y., Xie, X., Shen, X., Li, T., Li, S., Wu, C., & Liu, Y. (2017) · Biomaterials Science · doi:10.1039/c7bm00043j · Cited by 153
Chen, D., Si, W., Shen, J., Du, C., Lou, W., Bao, C., Zheng, H., Pan, J., Zhong, G., Xu, L., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-017-0211-4 · Cited by 169
iRGD Peptide as a Tumor-Penetrating Enhancer for Tumor-Targeted Drug Delivery
Kang, S., Lee, S., & Park, S. (2020) · Polymers · doi:10.3390/polym12091906 · Cited by 139
Pharmacogenetics for individualized cancer chemotherapy
Efferth, T., & Volm, M. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.02.005 · Cited by 169
Li, F., Mei, H., Gao, Y., Xie, X., Nie, H., Li, T., Zhang, H., & Jia, L. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.08.030 · Cited by 152
Understanding polyspecificity of multidrug ABC transporters: closing in on the gaps in ABCB1
Gutmann, D. A. P., Ward, A. B., Urbatsch, I. L., Chang, G. A., & van Veen, H. W. (2009) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2009.07.009 · Cited by 152
Lassalle, B., Bastos, H., Louis, J. P., Riou, L., Testart, J., Dutrillaux, B., Fouchet, P., & Allemand, I. (2003) · Development · doi:10.1242/dev.00918 · Cited by 166
“Some members (MDR1, BCRP1/ABCG2) of the ATP-binding cassette (ABC) transporter family contribute to the dye efflux component of the SP phenotype (reviewed by Gottesman et al., 2002; Bunting, 2002).”
BackgroundJansen, G., Scheper, R. J., & Dijkmans, B. A. C. (2003) · Scandinavian Journal of Rheumatology · doi:10.1080/03009740310004333 · Cited by 243
“ABCC1 MRP1 MTX, Chloroquine LTC4, LTB4, LTE4 MK571, probenecid, (25, 90, 108, 128, 165) Folates NSAIDs, flavonoids, CHQ (158, 183, 208) ABCC2 MRP2 MTX Bile salts, LTC4, steroids Sulphinpyrazone (25, 90) ABCC3 MRP3 MTX Bile salts, LTC4, steroids Probenecid (91, 92, 94, 95) ABCC4 MRP4 MTX, Azathioprine (6-MP) LTE4, cAMP…”
Quercetin Potentiates Doxorubicin Mediated Antitumor Effects against Liver Cancer through p53/Bcl-xl
Wang, G., Zhang, J., Liu, L., Sharma, S. P., & Dong, Q. (2012) · PLoS ONE · doi:10.1371/journal.pone.0051764 · Cited by 151
“However, studies have shown that some cancer cells, including hepatoma, are resistant to the apoptotic effects of DOX [3].”
Background
Metadata
- Authors
- Gottesman, M. M., Fojo, T., & Bates, S. E.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- Fojo, Tito
- Venue
- Nature Reviews Cancer
- Published
- 2002-01-01
- Volume
- 2
- Issue
- 1
- Pages
- 48-58
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2006434892
- Cited by
- 5,536
- References
- 168
- Citations by year
- 2026: 144 · 2025: 173 · 2024: 183 · 2023: 228 · 2022: 231 · 2021: 257 · 2020: 305 · 2019: 281 · 2018: 318 · 2017: 322 · 2016: 329 · 2015: 333 · 2014: 326 · 2013: 296 · 2012: 274
- FWCI
- 14.32
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › ATP Synthase and ATPases Research
- Keywords
- multidrug resistance, drug efflux pumps, chemoresistance, cancer chemotherapy, drug resistance mechanisms, metastatic cancer
- MeSH terms
- Adenosine Triphosphate, Antineoplastic Agents, Breast Neoplasms, Female, Forecasting, Multigene Family, Humans, Leukemia, Neoplasm Proteins, Neoplasms, Organ Specificity, Permeability, Structure-Activity Relationship, Drug Design, Xenobiotics, Biomarkers, Drug Resistance, Multiple, ATP-Binding Cassette Transporters, Drug Resistance, Neoplasm, ATP Binding Cassette Transporter, Subfamily B, Member 1, ATP-Binding Cassette, Sub-Family C Proteins, Multidrug Resistance-Associated Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.